Alnylam Pharmaceuticals
ALNY
258 hedge funds and large institutions have $5.24B invested in Alnylam Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 82 increasing their positions, 83 reducing their positions, and 20 closing their positions.
76% more call options, than puts
Call options by funds: $65.5M | Put options by funds: $37.2M
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
27% more capital invested
Capital invested by funds: $4.11B → $5.24B (+$1.13B)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
4% more funds holding
Funds holding: 248 → 258 (+10)
1% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 83
Top Buyers
| 1 |
Dodge & Cox
San Francisco,
California
|
+$195M |
| 2 |
BM
Bridger Management
New York
|
+$20.9M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$18.4M |
| 4 |
Goldman Sachs
New York
|
+$17.6M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$11.4M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$18.6M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$16.3M |
| 3 |
Jennison Associates
New York
|
-$13.7M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$10.2M |
| 5 |
ZBI
Ziff Brothers Investments
New York
|
-$8.04M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
276
Bessemer Group
Woodbridge,
New Jersey
| – | -$3K | -55 | Closed |
|
|
ASN
277
Advisory Services Network
Atlanta,
Georgia
| – | -$1K | -10 | Closed |
|
ALNY Hedge Fund Activity: Q3 2016 in Review
258 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2016, worth a combined $5.24B — up 27% from $4.11B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ALNY positions and 20 closed out — a net gain of 13 holders — while 82 added to existing stakes and 83 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $195M. The largest seller was Deerfield Management, exiting entirely with an estimated $18.6M sold.
- 258 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2016, up from 248 in Q2 2016.
- Funds reported $5.24B of Alnylam Pharmaceuticals stock for Q3 2016, up 27% quarter-over-quarter.
- 33 funds opened new Alnylam Pharmaceuticals positions in Q3 2016 and 20 closed out, a net change of +13 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2016 was Dodge & Cox, an estimated $195M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2016 was Deerfield Management, an estimated $18.6M sold.
Based on aggregated 13F filings for Q3 2016.